In patients with sickle cell disease, therapy with crizanlizumab, an antibody against the adhesion molecule P-selectin, resulted in a significantly lower rate of sickle cell-related pain crises than placebo, a trial in 198 patients aged from 16 to 65 years showed.
A 2-month-old African American girl who presented to the emergency department with 2 episodes of apnea or gasping respirations associated with feeds is admitted by your general inpatient pediatric service.
Expand treatment of sickle cell disease with 2 “underused” preventive therapies to reduce painful flare-ups, an expert panel convened by the National Heart, Lung, and Blood Institute urges in new management guidelines.
An expert panel of specialists from the National Heart, Lung, and Blood Institute has issued new guidelines for the management and treatment of sickle cell disease (SCD). How will these latest evidence-based recommendations affect the care of your patients?